The Coca-Cola Company (KO) vs Arcadia Biosciences, Inc. (RKDA)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| KO | RKDA | |
|---|---|---|
| Sector | Consumer Defensive | Consumer Defensive |
| Industry | Beverages - Non-Alcoholic | Packaged Foods |
| Size band | MEGA | NANO |
| Listing | NYSE | Nasdaq CM |
| Country | United States | United States |
| Theme | non-alcoholic-beverages | non-alcoholic-beverages |
| Price and returns | ||
| Last close | $92.70 | $0.15 |
| Return · 1 week | −0.77% | +4.69% |
| Return · 1 month | +6.33% | −50.71% |
| Return · 3 months | +5.02% | −75.90% |
| Return · year to date | +35.04% | −92.94% |
| Return · 1 year | +34.16% | −96.20% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −2.80% | −96.82% |
| 52-week high | $95.37 | $4.78 |
| 52-week low | $67.27 | $0.11 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $398.89B | $389.33K |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $1.37B | $23.50K |
| Employees | 65,900 | 8 |
| Valuation | ||
| Price to earnings · trailing | 28.20× | n/a (negative earnings) |
| Price to earnings · forward | 26.65× | n/a (negative forward earnings) |
| Price to sales | 8.06× | 0.08× |
| Price to book | 11.18× | 0.57× |
| Enterprise value to EBITDA | 25.54× | n/a (negative enterprise value and EBITDA) |
| Enterprise value to revenue | 8.66× | n/a (negative enterprise value) |
| PEG ratio | 4.27 | — |
| Earnings per share · trailing | 3.33 | -4.55 |
| Profitability | ||
| Gross margin | 61.89% | 34.60% |
| Operating margin | 34.87% | −34.37% |
| Profit margin | 28.56% | −234.53% |
| Return on equity | 42.05% | −430.93% |
| Return on assets | 9.40% | −34.76% |
| Growth | ||
| Revenue growth | +6.70% | −0.80% |
| Earnings growth | +16.90% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 115.52 | — |
| Current ratio | 1.31 | 3.49 |
| Dividend yield | 2.26% | 0.00% |
| Payout ratio | 62.46% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 59.68 | 22.02 |
| ADX · 14 | 29.80 | 23.30 |
| 50-day average | $89.20 | $0.38 |
| 200-day average | $81.71 | $1.08 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 1.80% | 23.30% |
The full KO analysis
Everything this table leaves out for The Coca-Cola Company: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the KO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full KO analysisThe full RKDA analysis
Everything this table leaves out for Arcadia Biosciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the RKDA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full RKDA analysis